Overview Dividends

(ICLR) ICON - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE0005711209

Clinical Trials, Laboratory Services, Consulting, Commercialization

Life Sciences Tools & Services
Market Cap in USD: 15,670m
IPO / Inception: 1998-05-15
Return 12m vs S&P 500: -23.1%

EPS (Earnings per Share)

EPS (Earnings per Share) of ICLR over the last years for every Quarter: "2020-12": 1.9, "2021-03": 2.06, "2021-06": 2.27, "2021-09": 2.55, "2021-12": 2.63, "2022-03": 2.76, "2022-06": 2.86, "2022-09": 3, "2022-12": 3.13, "2023-03": 2.9, "2023-06": 3.11, "2023-09": 3.3, "2023-12": 3.46, "2024-03": 3.47, "2024-06": 3.75, "2024-09": 3.35, "2024-12": 3.43, "2025-03": 3.19, "2025-06": 3.26, "2025-09": 3.31, "2025-12": 0,
EPS CAGR: -45.23%
EPS Trend: -31.4%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of ICLR over the last years for every Quarter: 2020-12: 760.229, 2021-03: 858.198, 2021-06: 871.155, 2021-09: 1866.352, 2021-12: 1885.121, 2022-03: 1901.764, 2022-06: 1935.193, 2022-09: 1942.427, 2022-12: 1962.002, 2023-03: 1978.578, 2023-06: 2020.251, 2023-09: 2055.099, 2023-12: 2066.248, 2024-03: 2090.386, 2024-06: 2120.159, 2024-09: 2030.03, 2024-12: 2041.101, 2025-03: 2001.332, 2025-06: 2017.357, 2025-09: 2042.812, 2025-12: null,
Rev. CAGR: 2.17%
Rev. Trend: 72.9%
Last SUE: 1.53
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 37.0%
Value at Risk 5%th 52.8%
Relative Tail Risk -13.40%
Reward TTM
Sharpe Ratio 0.02
Alpha -21.76
CAGR/Max DD -0.05
Character TTM
Hurst Exponent 0.526
Beta 0.929
Beta Downside 1.082
Drawdowns 3y
Max DD 63.43%
Mean DD 23.89%
Median DD 14.15%

Description: ICLR ICON January 03, 2026

ICON PLC (NASDAQ: ICLR) is a global contract research organization headquartered in Dublin that offers end-to-end outsourced services for drug and device development. Its portfolio spans strategic program design, Phase I-IV clinical trial execution, post-approval support, data analytics, decentralized and hybrid trial models, and a suite of laboratory services-including biomarker, vaccine, and GMP testing. ICON serves pharma, biotech, medical-device firms as well as government and public-health agencies across Ireland, Europe, the United States and other international markets.

Key recent metrics: FY 2023 revenue reached $4.9 billion, up ~7 % YoY, driven by strong demand for decentralized trial capabilities and real-world evidence solutions; the CRO industry is projected to grow at a CAGR of 7-8 % through 2028, underpinned by rising R&D spend (global pharma R&D outlays surpassed $210 billion in 2023) and tighter timelines for vaccine and oncology pipelines. ICON’s operating margin improved to 11.5 % as it leveraged scale efficiencies and higher-value services such as adaptive trial design and cardiac safety platforms.

For a deeper, data-driven assessment of ICON’s valuation relative to peers, you may find the analytics on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (599.5m TTM) > 0 and > 6% of Revenue (6% = 486.2m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA -1.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 2.34% (prev 11.56%; Δ -9.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.07 (>3.0%) and CFO 1.18b > Net Income 599.5m (YES >=105%, WARN >=100%)
Net Debt (3.10b) to EBITDA (1.18b) ratio: 2.63 <= 3.0 (WARN <= 3.5)
Current Ratio 1.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (78.1m) change vs 12m ago -6.43% (target <= -2.0% for YES)
Gross Margin 26.85% (prev 29.58%; Δ -2.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 48.06% (prev 48.26%; Δ -0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 3.96 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m) >= 6 (WARN >= 3)

Altman Z'' 1.17

(A) 0.01 = (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b
(B) 0.14 = Retained Earnings (Balance) 2.31b / Total Assets 16.51b
(C) 0.05 = EBIT TTM 790.0m / Avg Total Assets 16.86b
(D) 0.31 = Book Value of Equity 2.23b / Total Liabilities 7.17b
Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 52.73

1. Piotroski 5.50pt
2. FCF Yield 5.30%
3. FCF Margin 12.29%
4. Debt/Equity 0.38
5. Debt/Ebitda 2.63
6. ROIC - WACC (= -7.33)%
7. RoE 6.32%
8. Rev. Trend 72.89%
9. EPS Trend -31.43%

What is the price of ICLR shares?

As of January 08, 2026, the stock is trading at USD 202.92 with a total of 706,283 shares traded.
Over the past week, the price has changed by +11.36%, over one month by +11.43%, over three months by +8.72% and over the past year by -8.83%.

Is ICLR a buy, sell or hold?

ICON has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ICLR.
  • Strong Buy: 11
  • Buy: 0
  • Hold: 6
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ICLR price?

Issuer Target Up/Down from current
Wallstreet Target Price 207 2%
Analysts Target Price 207 2%
ValueRay Target Price 201.4 -0.7%

ICLR Fundamental Data Overview January 08, 2026

Market Cap USD = 15.67b (15.67b USD * 1.0 USD.USD)
P/E Trailing = 27.1903
P/E Forward = 14.4928
P/S = 1.9339
P/B = 1.6153
P/EG = 1.5409
Beta = 1.256
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 18.77b USD (15.67b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
FCF Yield = 5.30% (FCF TTM 995.8m / Enterprise Value 18.77b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 1.14 (Enterprise Value 18.77b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 93.82% (35.7m / 38.1m)
NOPAT = 48.8m (EBIT 790.0m * (1 - 93.82%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.63% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 0.38% (NOPAT 48.8m / Invested Capital 12.90b)
WACC = 7.70% (E(15.67b)/V(19.24b) * Re(9.44%) + D(3.57b)/V(19.24b) * Rd(1.41%) * (1-Tc(0.94)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF Debug] Terminal Value 71.43% ; FCFE base≈1.09b ; Y1≈980.1m ; Y5≈842.0m
Fair Price DCF = 157.3 (DCF Value 12.01b / Shares Outstanding 76.4m; 5y FCF grow -12.41% → 3.0% )
EPS Correlation: -31.43 | EPS CAGR: -45.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Quarter (2026-03-31): EPS=3.22 | Chg30d=-0.022 | Revisions Net=-3 | Analysts=13
EPS next Year (2026-12-31): EPS=13.31 | Chg30d=-0.187 | Revisions Net=-6 | Growth EPS=+1.8% | Growth Revenue=+0.4%

Additional Sources for ICLR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle